Biotechnology
119 US-listed companies in this industry.
Companies
119 listed
| Company | Revenue | Net income | Margin | ROE | Revenue 5y | Years |
|---|---|---|---|---|---|---|
| AMGNAMGEN INC | $36.75 B | $7.71 B | 21.0% | 106.1% | +7.6% | 19 |
| GILDGILEAD SCIENCES, INC. | $29.44 B | $8.51 B | 28.9% | 40.5% | +3.6% | 19 |
| BIIBBIOGEN INC. | $9.89 B | $1.29 B | 13.1% | 7.4% | -6.0% | 19 |
| ARGXARGENX SE | $4.15 B | $1.29 B | 31.1% | 20.2% | +151.5% | 11 |
| NBIXNEUROCRINE BIOSCIENCES INC | $2.86 B | $478.6 M | 16.7% | 16.4% | +22.3% | 17 |
| EXELEXELIXIS, INC. | $2.32 B | $782.6 M | 33.7% | 35.5% | +18.6% | 17 |
| QGENQIAGEN N.V. | $2.09 B | $424.9 M | 20.3% | 11.6% | +2.2% | 18 |
| MRNAModerna, Inc. | $1.94 B | -$2.82 B | -145.2% | -28.9% | +19.3% | 10 |
| HALOHALOZYME THERAPEUTICS, INC. | $1.40 B | $316.9 M | 22.7% | 153.6% | +39.2% | 17 |
| TECHBIO-TECHNE Corp | $1.22 B | $181.9 M | 15.0% | 9.0% | +5.5% | 18 |
| NVAXNOVAVAX INC | $1.12 B | $440.3 M | 39.2% | · | +18.8% | 16 |
| BCRXBIOCRYST PHARMACEUTICALS INC | $874.8 M | $263.9 M | · | · | +117.9% | 17 |
| RGENREPLIGEN CORP | $738.3 M | $48.9 M | 6.6% | 2.4% | +15.0% | 16 |
| ALVOAlvotech | $586.3 M | $27.9 M | 4.8% | · | +54.5% | 6 |
| ADMAADMA BIOLOGICS, INC. | $510.2 M | $146.9 M | 28.8% | 35.6% | +64.6% | 15 |
| TARSTarsus Pharmaceuticals, Inc. | $451.4 M | -$66.4 M | -14.7% | -23.4% | · | 6 |
| KRYSKrystal Biotech, Inc. | $389.1 M | $204.8 M | 52.6% | 18.9% | · | 5 |
| TWSTTwist Bioscience Corp | $376.6 M | -$77.7 M | -20.6% | -16.4% | +33.1% | 9 |
| ADPTAdaptive Biotechnologies Corp | $277.0 M | -$59.5 M | -21.5% | -28.2% | +23.0% | 9 |
| VCELVericel Corp | $276.3 M | $16.5 M | 6.0% | 5.1% | +17.3% | 17 |
| BEAMBeam Therapeutics Inc. | $139.7 M | -$80.0 M | -57.2% | -8.1% | +466.3% | 7 |
| IBRXImmunityBio, Inc. | $113.3 M | -$351.4 M | -310.2% | · | +184.8% | 13 |
| RXRXRECURSION PHARMACEUTICALS, INC. | $74.7 M | -$644.8 M | -863.4% | -59.5% | +79.9% | 7 |
| VIRVir Biotechnology, Inc. | $68.6 M | -$438.0 M | -638.9% | -45.7% | -2.1% | 9 |
| KYMRKymera Therapeutics, Inc. | $39.2 M | -$311.4 M | -794.0% | -25.8% | +2.9% | 7 |
| MESOMESOBLAST LTD | $17.2 M | -$102.1 M | -593.9% | -19.0% | -11.8% | 10 |
| RLAYRelay Therapeutics, Inc. | $15.4 M | -$276.5 M | · | -41.1% | -28.6% | 6 |
| CGONCG Oncology, Inc. | $4.0 M | -$161.0 M | · | -21.7% | · | 3 |
| CRSPCRISPR Therapeutics AG | $3.5 M | -$581.6 M | · | -30.2% | +37.3% | 11 |
| DNLIDenali Therapeutics Inc. | $0 | -$512.5 M | · | -45.7% | · | 10 |
| RVMDRevolution Medicines, Inc. | $0 | -$1.13 B | · | -58.1% | · | 8 |
| BNTXBioNTech SE | EUR 2.87 B | -EUR 1.14 B | -39.6% | -5.9% | +42.9% | 9 |
| IMCRImmunocore Holdings plc | GBP 143.7 M | -GBP 41.2 M | -28.7% | -18.3% | · | 5 |
| IOVAIOVANCE BIOTHERAPEUTICS, INC. | $263.5 M | -$391.0 M | -148.4% | -55.5% | · | 13 |
| VXRTVaxart, Inc. | $237.3 M | $16.3 M | · | 22.3% | +125.8% | 17 |
| DNAGinkgo Bioworks Holdings, Inc. | $170.2 M | -$312.8 M | -183.8% | -51.1% | +17.3% | 7 |
| AGENAGENUS INC | $114.2 M | -$3.1 M | -2.7% | · | +5.3% | 17 |
| CLLSCellectis S.A. | $72.9 M | -$67.6 M | -92.7% | -65.3% | +7.4% | 11 |
| CGENCOMPUGEN LTD | $72.8 M | $35.3 M | 48.6% | 44.8% | +105.2% | 14 |
| CHRSCoherus Oncology, Inc. | $42.2 M | $168.0 M | 398.4% | · | · | 14 |
| VYGRVoyager Therapeutics, Inc. | $40.4 M | -$119.7 M | -296.5% | -48.3% | -25.1% | 11 |
| ALECAlector, Inc. | $21.0 M | -$142.9 M | -679.2% | -181.6% | -0.1% | 9 |
| VALNValneva SE | EUR 174.7 M | -EUR 115.2 M | -66.0% | · | +9.6% | 7 |
| IPHAInnate Pharma SA | EUR 9.0 M | -EUR 49.2 M | -546.1% | · | -33.6% | 9 |
| ADAPYAdaptimmune Therapeutics PLC | $178.0 M | -$70.8 M | -39.8% | -275.7% | +175.5% | 11 |
| RGNXREGENXBIO Inc. | $170.4 M | -$193.9 M | -113.8% | -107.0% | +2.0% | 13 |
| ATRAAtara Biotherapeutics, Inc. | $120.8 M | $32.7 M | · | · | · | 4 |
| STROSUTRO BIOPHARMA, INC. | $102.5 M | -$191.1 M | -186.5% | · | +19.1% | 10 |
| FDMT4D Molecular Therapeutics, Inc. | $85.2 M | -$140.1 M | · | -27.6% | +44.3% | 7 |
| MGTXMeiraGTx Holdings plc | $81.4 M | -$114.2 M | -140.3% | · | +39.2% | 7 |
| AUTLAutolus Therapeutics plc | $75.4 M | -$287.5 M | -381.4% | -95.0% | · | 7 |
| BDTXBlack Diamond Therapeutics, Inc. | $70.0 M | $22.4 M | 32.0% | 22.9% | · | 5 |
| CSBRCHAMPIONS ONCOLOGY, INC. | $59.4 M | -$1.2 M | · | -30.5% | +7.7% | 16 |
| PLXProtalix BioTherapeutics, Inc. | $52.7 M | -$6.6 M | -12.5% | -14.4% | -3.5% | 17 |
| FENCFENNEC PHARMACEUTICALS INC. | $44.6 M | -$9.7 M | -21.8% | · | · | 14 |
| EDITEditas Medicine, Inc. | $40.5 M | -$160.1 M | -395.0% | -198.1% | -14.9% | 10 |
| SGMOQSANGAMO THERAPEUTICS, INC | $39.6 M | -$122.9 M | -310.8% | · | -19.7% | 17 |
| CCCCC4 Therapeutics, Inc. | $35.9 M | -$105.0 M | -292.1% | -44.4% | · | 5 |
| XFORX4 Pharmaceuticals, Inc | $35.1 M | -$79.2 M | -225.6% | -76.0% | · | 8 |
| DTILPRECISION BIOSCIENCES INC | $34.3 M | -$45.7 M | -133.4% | -61.5% | +7.1% | 8 |
| LCTXLineage Cell Therapeutics, Inc. | $14.6 M | -$63.5 M | -435.3% | -103.4% | +51.5% | 17 |
| TSHATaysha Gene Therapies, Inc. | $9.8 M | -$109.0 M | -1115.3% | -68.5% | · | 4 |
| CRISCURIS INC | $9.4 M | -$7.6 M | -80.3% | · | -2.7% | 17 |
| EVAXEvaxion A/S | $7.5 M | -$7.7 M | -102.4% | · | · | 4 |
| FATEFATE THERAPEUTICS INC | $6.6 M | -$136.3 M | · | -51.8% | -26.7% | 14 |
| DBVTDBV Technologies S.A. | $5.6 M | -$146.9 M | · | -149.8% | -13.0% | 7 |
| ZEOXZeo ScientifiX, Inc. | $5.2 M | -$5.5 M | · | · | +11.2% | 15 |
| PRMEPrime Medicine, Inc. | $4.6 M | -$201.1 M | · | -146.8% | · | 6 |
| OCGNOcugen, Inc. | $4.4 M | -$67.8 M | · | · | · | 12 |
| SRZNSurrozen, Inc. | $3.5 M | -$242.0 M | · | · | · | 5 |
| DYAIDYADIC INTERNATIONAL INC | $3.1 M | -$7.4 M | -238.3% | -397.8% | +14.0% | 9 |
| OTLKOutlook Therapeutics, Inc. | $1.4 M | -$62.4 M | · | · | · | 6 |
| PLURPluri Inc. | $1.0 M | -$23.8 M | · | · | · | 13 |
| IMAImageneBio, Inc. | $800,000 | -$45.3 M | · | · | -38.6% | 6 |
| CRDFCardiff Oncology, Inc. | $593,000 | -$45.9 M | · | -71.5% | +10.1% | 15 |
| ATYRaTYR PHARMA INC | $190,000 | -$74.1 M | · | -107.8% | · | 7 |
| ZIVOZivo Bioscience, Inc. | $157,220 | -$13.4 M | · | · | · | 14 |
| VIVSVivoSim Labs, INC. | $131,000 | -$13.8 M | · | · | · | 15 |
| AIMAIM ImmunoTech Inc. | $88,000 | -$14.0 M | · | · | -11.6% | 17 |
| INMBInmune Bio, Inc. | $50,000 | -$45.9 M | · | -165.2% | +35.4% | 8 |
| ENTXEntera Bio Ltd. | $42,000 | -$11.4 M | · | -108.0% | · | 6 |
| CKDXFOpthea Ltd | $25,000 | -$162.8 M | · | · | -15.8% | 7 |
| CELZCREATIVE MEDICAL TECHNOLOGY HOLDINGS, | $6,000 | -$6.0 M | · | -86.5% | -48.4% | 16 |
| ALLOAllogene Therapeutics, Inc. | $0 | -$190.9 M | · | -53.4% | · | 7 |
| APTOFAptose Biosciences Inc. | $0 | -$25.5 M | · | · | · | 6 |
| BCDABioCardia, Inc. | $0 | -$8.2 M | · | -950.1% | · | 13 |
| CMPXCompass Therapeutics, Inc. | $0 | -$66.5 M | · | -41.3% | · | 3 |
| ELOXEloxx Pharmaceuticals, Inc. | $0 | -$6.0 M | · | · | · | 7 |
| PALIPALISADE BIO, INC. | $0 | -$16.8 M | · | -24.5% | · | 15 |
| PMCBPharmaCyte Biotech, Inc. | $0 | -$19.4 M | · | -45.6% | · | 16 |
| SRRKScholar Rock Holding Corp | $0 | -$377.9 M | · | -123.1% | · | 6 |
| ABPOAbpro Holdings, Inc. | · | -$2.9 M | · | · | · | 2 |
| AGTXAgentix Corp. | · | -$485,636 | · | · | · | 5 |
| ALGSAligos Therapeutics, Inc. | · | -$24.2 M | · | · | · | 5 |
| AURAAura Biosciences, Inc. | · | -$106.2 M | · | -73.5% | · | 0 |
| BCABBioAtla, Inc. | · | -$59.6 M | · | · | · | 1 |
| CABACabaletta Bio, Inc. | · | -$167.9 M | · | -127.0% | · | 0 |
| CGEMCullinan Therapeutics, Inc. | · | -$219.9 M | · | -44.0% | · | 3 |
| CVMCEL SCI CORP | · | -$25.4 M | · | -176.3% | · | 4 |
| ENGNenGene Therapeutics Inc. | · | -$117.3 M | · | -53.3% | · | 0 |
| IKTInhibikase Therapeutics, Inc. | · | -$48.3 M | · | -36.0% | · | 3 |
| MOLNMOLECULAR PARTNERS AG | CHF 0 | -CHF 61.7 M | · | -55.5% | · | 7 |
| SLDBSolid Biosciences Inc. | · | -$174.3 M | · | -109.9% | · | 7 |
| VISKViskase Holdings, Inc. | · | -$3.4 M | · | · | · | 15 |
| WINTWINDTREE THERAPEUTICS INC | · | -$1.8 M | · | -26.7% | · | 8 |
| GLUEMonte Rosa Therapeutics, Inc. | $123.7 M | -$38.6 M | -31.2% | -16.9% | · | 3 |
| IPSCCentury Therapeutics, Inc. | $109.2 M | -$9.6 M | -8.8% | -6.0% | · | 4 |
| IVVDInvivyd, Inc. | $53.4 M | -$52.5 M | -98.2% | -34.0% | · | 3 |
| SCLXScilex Holding Co | $30.3 M | -$374.1 M | -1236.4% | · | +5.1% | 6 |
| MGXMetagenomi Therapeutics, Inc. | $25.2 M | -$87.9 M | -348.5% | -44.7% | · | 3 |
| ELUTELUTIA INC. | $12.3 M | $53.4 M | 434.2% | · | -22.0% | 7 |
| CRBUCaribou Biosciences, Inc. | $11.2 M | -$148.1 M | -1327.4% | -79.0% | -2.0% | 7 |
| TCRXTScan Therapeutics, Inc. | $10.3 M | -$129.8 M | -1256.8% | -71.3% | +56.9% | 6 |
| INBXInhibrx Biosciences, Inc. | $1.3 M | -$140.1 M | · | -197.8% | · | 3 |
| PROKPROKIDNEY CORP. | $893,000 | -$69.0 M | · | · | · | 4 |
| SNTISenti Biosciences Holdings, Inc. | $22,000 | -$61.4 M | · | -393.4% | · | 5 |
| ARTVArtiva Biotherapeutics, Inc. | $0 | -$83.9 M | · | -56.5% | · | 3 |
| SABSSAB Biotherapeutics, Inc. | $0 | $13.3 M | · | 15.0% | · | 6 |
| CADLCandel Therapeutics, Inc. | · | -$38.2 M | · | -64.6% | · | 3 |
"·" marks a figure not available in our data.